Imatinib, a small molecule BCR-ABL specific tyrosine kinase inhibitor (TKI), is the first-line of therapy for CML and helps to achieve a complete cytogenetic response (CCR) in more than 80% of the patients4. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.